Preoperative screening and prehabilitation strategies prior to ileocolic resection in patients with Crohn’s disease are not incorporated in routine care.
Bak MTJ, van Ruler O, Stassen L, Ruiterkamp M, Arkenbosch JHC, Dijkstra G, Campmans-Kuijpers MJE, van Meeteren NLU, Bongers BC, Romberg-Camps M, van der Marel S, Hoentjen F, van Dongen KW, West R, van der Woude J, de Vries AC; Dutch Initiative Crohn and Colitis (ICC)...
Therapeutic drug monitoring of methotrexate in patients with Crohn’s disease
van de Meeberg MM, Fidder HH, Oldenburg B, Sundaresan J, Struys EA, Montazeri NSM, Mares WGN, Mahmmod N, van Asseldonk DP, Lutgens MWMD, Kuyvenhoven JP, Rietdijk ST, Nissen LHC, Koehestanie P, de Boer NKH, de Jonge R, Bouma G, Bulatović Ćalasan M; Dutch Initiative on...
Prognostic value of the modified Rutgeerts’ score for long-term outcomes after primary ileocecal resection in Crohn’s disease
Bak MTJ, Huinink STB, Erler NS, Bodelier AGL, Dijkstra G, Romberg-Camps MJ, de Boer NKH, Hoentjen F, Stassen LPS, van der Meulen-de Jong AE, West RL, van Ruler O, van der Woude CJ, de Vries AC; Dutch Initiative on Crohn and Colitis (ICC); Dutch Initiative on Crohn and...
Smoking and colorectal neoplasia in patients with inflammatory bowel disease: Dose-effect relationship
Wijnands AM, Elias SG, Dekker E, Fidder HH, Hoentjen F, Ten Hove JR, Maljaars PWJ, van der Meulen-de Jong AE, Mooiweer E, Ouwehand RJ, Penning de Vries BBL, Ponsioen CY, van Schaik FDM, Oldenburg B; Dutch Initiative on Crohn's and Colitis (ICC). United European...
Cumulative exposure to immunomodulators increases risk of cervical neoplasia in women with inflammatory bowel disease
Kreijne JE, Goetgebuer RL, Erler NS, De Boer NK, Siebers AG, Dijkstra G, van Kemenade FA, Hoentjen F, Oldenburg B, van der Meulen AE, Ponsioen CIJ, Pierik MJ, van der Woude CJ, de Vries AC; Dutch Initiative on Crohn and Colitis (ICC). Aliment Pharmacol Ther. 2023...
[Inflammatory bowel disease]
Straatmijer T, Duijvestein M, van Dop W, Stassen L, Derikx M, Bureo, Gonzalez A, Mujagic Z, Pierik M, van Schaik F, Peters C, Derikx L, de Groof J, Bennebroek Evertsz F, van der Bilt J, Visschedijk M, West R, Romkens T, van der Meulen A Ned Tijdschr Geneeskd. 2023 Aug...
Endoscopic and surgical treatment outcomes of colitis-associated advanced colorectal neoplasia: a multicenter cohort study
Derks ME, Te Groen M, Peters CP, Dijkstra G, de Vries AC, Romkens TE, Horjus CS, de Boer NK, Bemelman WA, Nagtegaal ID, Derikx LA, Hoentjen F; Dutch Initiative on Crohn and Colitis. Int J Surg. 2023 Jul 1;109(7):1961-1969. doi: 10.1097/JS9.0000000000000335. Free PMC...
Cost-effectiveness analysis of increased adalimumab dose intervals in Crohn’s disease patients in stable remission: the randomised controlled LADI trial
Jansen FM, van Linschoten RCA, Kievit W, Smits LJT, Pauwels RWM, de Jong DJ, de Vries AC, Boekema PJ, West RL, Bodelier AGL, Gisbertz IAM, Wolfhagen FHJ, Römkens TEH, Lutgens MWMD, van Bodegraven AA, Oldenburg B, Pierik MJ, Russel MGVM, de Boer NK, Mallant-Hent RC,...
Ustekinumab Trough Concentrations Are Associated with Biochemical Outcomes in Patients with Crohn’s Disease
Straatmijer T, Biemans VBC, Moes DJAR, Hoentjen F, Ter Heine R, Maljaars PWJ, Theeuwen R, Pierik M, Duijvestein M, van der Meulen-de Jong AE; Dutch Initiative on Crohn’s and Colitis (ICC). Dig Dis Sci. 2023 Jun;68(6):2647-2657. doi: 10.1007/s10620-023-07822-7. Epub...
Increased versus conventional adalimumab dose interval for patients with Crohn’s disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trial
van Linschoten RCA, Jansen FM, Pauwels RWM, Smits LJT, Atsma F, Kievit W, de Jong DJ, de Vries AC, Boekema PJ, West RL, Bodelier AGL, Gisbertz IAM, Wolfhagen FHJ, Römkens TEH, Lutgens MWMD, van Bodegraven AA, Oldenburg B, Pierik MJ, Russel MGVM, de Boer NK,...